StockData

IGC Pharma vs Longeveron

IGC and LGVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IGC and LGVN compare

Longeveron is the larger company, worth 3.5 times as much as IGC Pharma ($67.3M against $19.4M).

IGC Pharma grew revenue faster over the last twelve months (−15.4% versus −42.7% for Longeveron).

IGC Pharma keeps more of each dollar of sales as profit, with a net margin of −702% compared with −1978% at Longeveron.

Longeveron scores higher on the StockData Score (5 against 2 for IGC Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIGCLGVN
Size and price
Market cap$19.4M$67.3M
Share price$0.188$2.11
Change, 1 year−47.5%−69.0%
Change, 5 years−86.2%−99.9%
Beta (5Y)0.821.44
Employees6737
StockData Score
Total score25 (better)
Valuation score00
Growth score00
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S17.3× (better)56.7×
P/B3.2× (better)6.5×
FCF yield–−30.5%
Fair value$0.158–
Margin of safety−18.9%–
Growth
Revenue growth (TTM)−15.4% (better)−42.7%
Revenue growth, 5Y average–−26.6%
Profitability
Gross margin21.9%69.8% (better)
Operating margin−987% (better)−1993%
Net margin−702% (better)−1978%
FCF margin–−1730%
Return on equity−129% (better)−204%
Return on invested capital−150% (better)−1412%
Financial health
Debt / equity0.02 (better)0.00
Current ratio0.392.63 (better)
Altman Z-score−19.71−9.42 (better)
Piotroski F-score–1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.1%1.5%
Held by insiders13.2%43.8%
Short interest, % of float0.44%0.88%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.